Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2356MR)

This product GTTS-WQ2356MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2356MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10967MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ3142MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ2037MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ15139MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ7064MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ3349MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ6920MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ3245MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-113
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW